* Entero Therapeutics Inc reported a quarterly adjusted loss of $3.37 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-37.80. The mean expectation of two analysts for the quarter was for a loss of $1.55 per share.
* Reported revenue was zero; analysts expected zero.
* Entero Therapeutics Inc's reported EPS for the quarter was a loss of $3.86.
* The company reported a quarterly loss of $8.85 million.
* Entero Therapeutics Inc shares had risen by 114.7% this quarter and lost 82.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "hold."
Wall Street's median 12-month price target for Entero Therapeutics Inc is $36.00 This summary was machine generated from LSEG data October 21 at 10:13 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -1.55 -3.37 Missed
Mar. 31 2024 -2.43 -0.64 Beat
Dec. 31 2023 -4.03 -5.35 Missed
Sep. 30 2023 -12.30 -9.20 Beat
Comments